BofA raised the firm’s price target on Argenx (ARGX) to $774 from $770 and keeps a Buy rating on the shares. The company pre-announced Q4 ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Denver Location Boasts Private Infusion Suites for Addressing Patients’ Specialty Therapy Needs Soleo Health, an innovative ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Prescott Park Arts Festival's Sweetheart Deal is back PORTSMOUTH — Prescott Park Arts Festival has brought back their ...